Steven A. Cohen reports an Avalo Therapeutics (AVTX) stake but owns no shares directly.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen have reported a collective beneficial ownership of 1,625,019 Avalo Therapeutics, Inc. (AVTX) common shares, representing 3.0% of the class as of September 30, 2026. While they hold shared voting and dispositive power over these shares, none of the reporting persons directly own any Avalo shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.